Publications by authors named "J F Sanchez-Munoz-Torrero"
Article Synopsis
- The study focuses on the characteristics and long-term outcomes of patients with homozygous familial hypercholesterolemia (HoFH), a severe genetic condition affecting cholesterol levels and cardiovascular health.
- Data was collected from the SAFEHEART study between 2004 and 2022, analyzing 39 HoFH patients with a median follow-up of 11 years, revealing significant genetic and clinical variations among them.
- Results showed a high initial level of LDL cholesterol (median 555 mg/dL), but treatment greatly improved this (median 122 mg/dL), which also led to a reduction in atherosclerotic cardiovascular disease (ASCVD) events over time.
Background: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia.
View Article and Find Full Text PDFIntroduction: New anthropometric indices have been developed as an alternative to body mass index (BMI) and waist circumference (WC) to assess body mass and visceral fat. Asymptomatic hyperuricemia is considered an independent cardiovascular risk factor. Currently, little is known about the relationship between asymptomatic hyperuricemia and several new anthropometric indices.
View Article and Find Full Text PDFInterdigital and sole of the feet pruritus.
Enferm Infecc Microbiol Clin (Engl Ed)
October 2023
Background: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocumab by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of a noninvasive analysis of coronary computed tomographic angiography in asymptomatic subjects with familial hypercholesterolemia receiving optimized and stable treatment with maximum tolerated statin dose with or without ezetimibe.
Methods: This study is a phase IV, open-label, multicenter, single-arm clinical trial to assess changes in coronary plaque burden and its characteristics after 78 weeks of treatment with alirocumab in patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease.